Therefore, the Zacks rating upgrade for Celldex basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful ...

While Celldex has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one ...

Gross proceeds from the offering, excluding the exercise of the underwriters’ option, if any, are estimated to be approximately $400M. The biotechnology firm will use the net proceeds from the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock at the public offering price, less ...

Celldex Therapeutics (CLDX) closed the last trading session at $51.37, gaining 45.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...